Keyphrases
Asian Population
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Meta-analysis
100%
Treatment Effect
100%
Thiazolidinediones
100%
Glycated Hemoglobin
75%
Hemoglobin A1c (HbA1c)
75%
Pioglitazone
75%
Rosiglitazone
75%
Confidence Interval
50%
Glycemic Control
50%
Asian Patients
25%
Randomized Controlled Trial
25%
T2DM Patients
25%
Beneficial Effects
25%
Random Effects Model
25%
Long-term Efficacy
25%
Antidiabetic
25%
Long-term Safety
25%
Significant Benefit
25%
Weighted Mean Difference
25%
Safety Data
25%
Glycemic Outcomes
25%
Efficacy Data
25%
Patient-centered Outcomes
25%
Surrogate Outcomes
25%
Neuroscience
Diabetes Mellitus
100%
Meta-Analysis
100%
Thiazolidinedione
100%
Hemoglobin A1c
75%
Glycosylated Hemoglobin
75%
Rosiglitazone
75%
Pioglitazone
75%
Randomized Controlled Trial
25%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Thiazolidinedione
100%
Hemoglobin A1c
75%
Pioglitazone
75%
Glycosylated Hemoglobin
75%
Rosiglitazone
75%
Randomized Controlled Trial
25%
Random Effects Model
25%
Antidiabetic Agent
25%
Biochemistry, Genetics and Molecular Biology
Thiazolidinedione
100%
Glycated Hemoglobin
75%
Glycosylated Hemoglobin
75%
Rosiglitazone
75%
Pioglitazone
75%
Glycemic Control
50%
Randomized Controlled Trial
25%